Turkish Journal of Physical Medicine and Rehabilitation 2012 , Vol 58 , Num 1

Relation of BMI and Postmenopausal Duration With Antioxidant and Anti-Inflammatory Effects of Raloxifene Treatment in Women With Osteoporosis: A Preliminary Report

Yasemin Akçay 1 ,Sibel Eyigör 2 ,Bilal İlanbey 3 ,Muammer Karadeniz 4 ,Yeşim Kirazlı 5 ,Eser Sözmen 1
1 Ege Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Izmir, Türkiye
2 Department of Physical Medicine and Rehabilitation, Ege University Faculty of Medicine, İzmir, Turkey
3 Yozgat State Hospital, Department of Biochemistry, Yozgat, Turkey
4 Ege Üniversitesi, Tıp Fakültesi, Dahiliye, Endokrinoloji ve Metabolizma Anabilim Dalı, Izmir, Türkiye
5 Ege Üniversitesi Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, İzmir, Türkiye
DOI : 10.4274/tftr.61687

Objective: We have not identified any objective evidence in the literature about the effects of raloxifene treatment on the antioxidant and antiinflammatory markers. We investigated the antioxidant/anti-inflammatory effects of raloxifene and the association of its antioxidant/antiinflammatory effects with body mass index (BMI) and postmenopausal period in women with osteoporosis (OP).


Materials and Methods: Fourteen postmenopausal women with OP were enrolled in this study. Raloxifene hydrochloride 60 mg/day was administered for 6 months. The oxidant/antioxidant state was evaluated by measuring erythrocyte catalase (e-CAT) and paraoxonase (PON1) activities, levels of thiobarbituric acid (e-TBARS), serum diene, total antioxidant activity (AOA), trolox equivalent antioxidant capacity (TEAC), ferric reducing ability of plasma (FRAP) and anti-inflammatory effects were assessed by measuring tumor necrosis factor (TNF)-α, Interleukin (IL-6), IL-18, IL-10 and adiponectin levels. Plasma cytokine (TNF-alpha, IL-6, IL-10, IL-18) levels were measured by ELISA kits and antioxidant parameters were determined by spectrophotometry. Serum levels of all parameters were measured at baseline and end of the study.


Results: IL-6 level was significantly decreased but IL-10 and PON1 levels were significantly increased after the study treatment (p<0.05). Raloxifene treatment significantly decreased IL-6 levels when postmenopausal period was longer than 10 years and BMI was <30 kg/m2 (p<0.05).


Conclusion: Raloxifene resulted in a significant decrease in pro-inflammatory cytokine IL-6 and significant increases in anti-inflammatory cytokine IL-10 and antioxidant PON1 levels in women with OP. BMI and postmenopausal period are both associated with anti-inflammatory and antioxidant effects of raloxifene in postmenopausal period. 

Keywords : Raloxifene, anti-inflammatory, antioxidant effect